2020 Pipeline Insight on Refractory Epilepsy - Comprehensive Insights of Present Clinical Development Scenario and Growth Prospects

DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Refractory Epilepsy- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Refractory Epilepsy market. A detailed picture of the Refractory Epilepsy pipeline landscape is provided, which includes the disease overview and Refractory Epilepsy treatment guidelines.

The assessment part of the report embraces in-depth Refractory Epilepsy commercial assessment and clinical assessment of the Refractory Epilepsy pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Epilepsy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Refractory Epilepsy of pipeline development activities

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Refractory Epilepsy with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Refractory Epilepsy treatment.
• Refractory Epilepsy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Refractory Epilepsy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Companies Mentioned

• Aadi, LLC
• UCB Biopharma
• Cerebral Therapeutics LLC
• Centogene AG Rostock

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Refractory Epilepsy.
• In the coming years, the Refractory Epilepsy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Refractory Epilepsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Refractory Epilepsy treatment market. Several potential therapies for Refractory Epilepsy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Refractory Epilepsy market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Refractory Epilepsy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions Answered

1. What are the current options for Refractory Epilepsy treatment?
2. How many companies are developing therapies for the treatment of Refractory Epilepsy?
3. What are the principal therapies developed by these companies in the industry?
4. How many therapies are developed by each company for the treatment of Refractory Epilepsy?
5. How many Refractory Epilepsy emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Refractory Epilepsy?
6. Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
7. What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Refractory Epilepsy market?
8. Which are the dormant and discontinued products and the reasons for the same?
9. What is the unmet need for current therapies for the treatment of Refractory Epilepsy?
10. What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Refractory Epilepsy therapies?
11. What are the clinical studies going on for Refractory Epilepsy and their status?
12. What are the results of the clinical studies and their safety and efficacy?
13. What are the key designations that have been granted for the emerging therapies for Refractory Epilepsy?
14. How many patents are granted and pending for the emerging therapies for the treatment of Refractory Epilepsy?

Key Topics Covered:

1. Report Introduction

2. Refractory Epilepsy
2.1. Overview
2.2. History
2.3. Refractory Epilepsy Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Refractory Epilepsy Diagnosis
2.6.1. Diagnostic Guidelines

3. Refractory Epilepsy Current Treatment Patterns
3.1. Refractory Epilepsy Treatment Guidelines

4. Refractory Epilepsy - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Refractory Epilepsy companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Refractory Epilepsy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Refractory Epilepsy Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Refractory Epilepsy Late Stage Products (Phase-III)

7. Refractory Epilepsy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Refractory Epilepsy Discontinued Products

13. Refractory Epilepsy Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Refractory Epilepsy Key Companies

15. Refractory Epilepsy Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Refractory Epilepsy Unmet Needs

18. Refractory Epilepsy Future Perspectives

19. Refractory Epilepsy Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/d1eviu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets